|
|
 |
|
Viewing report
|
|
|
|
Monoclonal Antibodies Report: 2008 Update
Datamonitor, June 2008, Pages: 363
Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies are using to capitalize on this lucrative market
Introduction
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Scope
- Comprehensive financial strategic analysis of the mAb market out to 2013
- Global sales forecasts to 2013 for marketed and Phase III mAb products
- Analysis of market trends by product, company, therapy area, technology and target type
- Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The overall prescription pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the patent cliff. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2013.
mAbs currently command a three-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.
Reasons to Purchase
- Assess the key products that will drive sales growth in the mAb market to 2013
- Understand the challenges and barriers to entry for new players seeking to venture into the mAb market
- Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars
Customers who bought this item also bought
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
Monoclonal Antibodies Report Part I
UCB S.A.: PharmaVitae Profile
Boehringer Ingelheim GmbH: PharmaVitae Profile
Nycomed A/S: PharmaVitae Profile
Allergan Inc.: PharmaVitae Model
Watson Pharmaceuticals Inc.: PharmaVitae Model
Celgene Corporation: PharmaVitae Profile
Alcon Inc.: PharmaVitae Profile
Monoclonal Antibody Based Products - Global Strategic Business Report
Barr Pharmaceuticals Inc.: PharmaVitae Model
Monoclonal Antibodies Report Market Model
|
|
|
|
